Unity Biotechnology, Inc.
TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS

Last updated:

Abstract:

This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.

Status:
Application
Type:

Utility

Filling date:

10 Dec 2021

Issue date:

31 Mar 2022